Loading stock data…
PCSA
$2.55-0.13 (-4.85%)
Market ClosedLast close May 1
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Processa Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.55. The stock is currently near its 52-week low of $1.76, remaining 46.7% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why PCSA maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.55
Potential Upside
5%
Whystock Fair Value$2.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved onco...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-315.49%
Volume
Today's trading volume
35,268
Recent News
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
US stocks look set to open higher in Thursday's trading session as investors dissect key inflation a
Top Midday Gainers
Processa Pharmaceuticals (PCSA) said Wednesday that an update from its phase 2 study of a combinatio
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week
Insiders who bought US$213.4k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company’s comprehensive portfolio update just a few days […]